Related Experiment Video
Updated: Jan 10, 2026
06:27
Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
Published on: October 20, 2020
5.6K
Exploring Additional Strength Biowaiver Perspectives in the ICH M13B Framework for Immediate Release Solid Oral
Rajkumar Boddu1, Arvind Rachapally1, Mohammed Shareef Khan1
1Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd, Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad, Telangana, 500090, India.
Therapeutic Innovation & Regulatory Science
|November 25, 2025
Summary
The International Council for Harmonisation (ICH) M13B draft guidance harmonizes biowaiver criteria for additional generic drug strengths. This review compares ICH M13B with EMA and USFDA requirements, highlighting challenges and benefits for market entry.
Area of Science:
- Pharmaceutical Sciences
- Regulatory Affairs
- Drug Development
Background:
- Generic drug development requires demonstrating bioequivalence for market entry.
- Biowaivers for additional strengths streamline the regulatory process.
- Existing guidelines from EMA and USFDA have specific criteria for biowaivers.
Purpose of the Study:
- To review and compare the biowaiver criteria outlined in the draft ICH M13B guidance with those of the EMA and USFDA.
- To highlight the advantages and challenges associated with the ICH M13B guidance for additional strength biowaivers.
- To provide insights into the rationale, risks, and benefits of the revised dissolution similarity assessments in ICH M13B.
Main Methods:
- Comparative analysis of regulatory guidance documents (ICH M13B draft, EMA, USFDA).
- Review of criteria for pharmacokinetic linearity, formulation proportionality, and dissolution similarity.
- Assessment of the impact of proposed changes in dissolution similarity assessments.
Main Results:
- The ICH M13B guidance introduces harmonized biowaiver requirements for additional strengths.
- Significant changes in dissolution similarity assessments present both advantages and challenges.
- Comparison reveals differences and similarities between ICH M13B, EMA, and USFDA requirements.
Conclusions:
- The ICH M13B guidance offers a harmonized approach to additional strength biowaivers.
- Understanding the nuances of dissolution similarity assessment is critical for regulatory success.
- This review provides a roadmap for navigating regulatory submissions for additional strength biowaivers.
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
210
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
210
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
185
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
222
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
222
01:20Drug Product Performance: In Vitro–In Vivo Correlation
216
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
216
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
161
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
161
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
383
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
383